Literature DB >> 12399959

Causality of myelodysplasia and acute myeloid leukemia and their genetic abnormalities.

J Pedersen-Bjergaard1, D H Christiansen, M K Andersen, F Skovby.   

Abstract

New insights into causative factors for the development of myelodysplasia (MDS) and acute myeloid leukemia (AML), with associations to specific cytogenetic and genetic abnormalities have been obtained primarily from studies of patients with the therapy-related subsets of the two diseases. Current knowledge now makes it possible to distinguish between at least seven major genetic subgroups of MDS and AML, and has directed research towards more specific causative factors also for de novo MDS and AML.

Entities:  

Mesh：

Year:  2002        PMID： 12399959     DOI： 10.1038/sj.leu.2402764

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


  10 in total

Review 1.  Topics in pediatric leukemia--myelodysplastic and myeloproliferative disorders of childhood.

Authors:  Joseph Lasky; Kathleen M Sakamoto
Journal:  MedGenMed       Date:  2005-03-14

Review 2.  Epigenetic changes in the myelodysplastic syndrome.

Authors:  Jean-Pierre Issa
Journal:  Hematol Oncol Clin North Am       Date:  2010-04       Impact factor: 3.722

Review 3.  Meta-analysis of chromosomal aberrations as a biomarker of exposure in healthcare workers occupationally exposed to antineoplastic drugs.

Authors:  Christine Roussel; Kristine L Witt; Peter B Shaw; Thomas H Connor
Journal:  Mutat Res Rev Mutat Res       Date:  2017-08-24       Impact factor: 5.657

4.  Genetic abnormalities and challenges in the treatment of acute myeloid leukemia.

Authors:  C Chandra Kumar
Journal:  Genes Cancer       Date:  2011-02

5.  Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.

Authors:  Kjeld Schmiegelow; Ibrahim Al-Modhwahi; Mette Klarskov Andersen; Mikael Behrendtz; Erik Forestier; Henrik Hasle; Mats Heyman; Jon Kristinsson; Jacob Nersting; Randi Nygaard; Anne Louise Svendsen; Kim Vettenranta; Richard Weinshilboum
Journal:  Blood       Date:  2009-02-17       Impact factor: 22.113

Review 6.  Therapy-related acute myelogenous leukemia and myelodysplastic syndrome.

Authors:  Gautam Borthakur; And Elihu E Estey
Journal:  Curr Oncol Rep       Date:  2007-09       Impact factor: 5.075

7.  Large-scale identification of disease genes involved in acute myeloid leukemia.

Authors:  Stefan J Erkeland; Marijke Valkhof; Claudia Heijmans-Antonissen; Antoinette van Hoven-Beijen; Ruud Delwel; Mirjam H A Hermans; Ivo P Touw
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

8.  Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia.

Authors:  Hussein Fayyad-Kazan; Nizar Bitar; Mehdi Najar; Philippe Lewalle; Mohammad Fayyad-Kazan; Rabih Badran; Eva Hamade; Ahmad Daher; Nader Hussein; Rim ElDirani; Fadwa Berri; Luc Vanhamme; Arsène Burny; Philippe Martiat; Redouane Rouas; Bassam Badran
Journal:  J Transl Med       Date:  2013-02-07       Impact factor: 5.531

Review 9.  Molecular mechanisms of etoposide.

Authors:  Alessandra Montecucco; Francesca Zanetta; Giuseppe Biamonti
Journal:  EXCLI J       Date:  2015-01-19       Impact factor: 4.068

10.  The G⁵¹⁶T CYP2B6 germline polymorphism affects the risk of acute myeloid leukemia and is associated with specific chromosomal abnormalities.

Authors:  Aggeliki Daraki; Sophia Zachaki; Theodora Koromila; Paraskevi Diamantopoulou; Gabriel E Pantelias; Constantina Sambani; Vasiliki Aleporou; Panagoula Kollia; Kalliopi N Manola
Journal:  PLoS One       Date:  2014-02-24       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.